MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, December 20, 2014

MS Emerging therapies with odd names...

Date: December 20, 2014

First, to learn how to say these pharma names of these emerging therapies

Daclizumab (Dac-li-zu-mab)  (trade name Zenapax)
is a therapeutic humanized monoclonal antibody. It is used to prevent rejection in organ transplantation, especially in kidney transplants. The drug is also under investigation for the treatment of multiple sclerosis.

− DAC HYP Demonstrated Superiority Over Interferon Beta-1a in Annualized Relapse Rate –
− Positive Results Set Stage for Regulatory Filings –
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill. –  Biogen Idec and AbbVie  announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001).
“The results of the DECIDE study are compelling, with DAC HYP demonstrating robust efficacy compared to a current standard of MS care,” said Gilmore O’Neill, vice president, Global Neurology Clinical Development, Biogen Idec. “As a potential once-monthly therapy with a novel mechanism of action, we believe that, if approved, DAC HYP will be an important treatment option for people living with MS.”
Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T cells. The drug is marketed in the US, but not in Europe

Read more  here

Ocrelizumab  (Ocre-li-zu-mab)
is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It is under development by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.

Ocrelizumab in MS: Encouraging Long-term Data

Long-term follow-up of patients with multiple sclerosis (MS) in the phase 2 trial of ocrelizumab suggest that the drug continues to be effective for up to 18 months after the last dose, with no new safety concerns identified.
The latest data from the phase 2 study with the drug, a humanized monoclonal antibody targeted against CD20-expressing B cells, were presented by lead investigator Stephen Hauser, MD, here at the American Academy of Neurology (AAN) 65th Annual Meeting last week.
Results showed that patients having up to 4 treatment cycles of ocrelizumab and followed for as long as 18 months after the last dose had minimal new MRI activity and a low level of clinical disease activity. In addition, there were no new safety concerns and no reports of opportunistic infections.
"Major Blockbuster"?

 Keep CURRENT with MS Views and News - OPT-IN here


No comments: